About usOur scienceOur programsPatientsInvestorsCareers
Our programs

We are advancing a broad pipeline of potentially best-in-class antibodies

APG777
APG777+APG990
APG777+APG333
We believe that APG777 and our combination strategies will enable us to develop the most effective, safe options for people living with I&I conditions. APG777 has pipeline-in-a-product potential, and is currently being evaluated in atopic dermatitis, with plans to advance trials in asthma and eosinophilic esophagitis.
A 3D visualization of an APG777 molecular structure. The molecule is an antibody with modifications highlighted in bright glowing blue shade.A 3D visualization of the APG777 and APG990 molecular structures. These molecules are antibodies with modifications highlighted in bright glowing blue shade.A 3D visualization of the APG777 and APG333 molecular structures. These molecules are antibodies with modifications highlighted in bright glowing blue shade.A 3D visualization of an APG777 molecular structure. The molecule is an antibody with modifications highlighted in bright glowing blue shade.A 3D visualization of the APG777 and APG990 molecular structures. These molecules are antibodies with modifications highlighted in bright glowing blue shade.A 3D visualization of the APG777 and APG333 molecular structures. These molecules are antibodies with modifications highlighted in bright glowing blue shade.

Our combination strategies will look to break through the efficacy ceilings in I&I indications. But first, we must evaluate each individual investigational therapy in a Phase 1 healthy volunteers trial to confirm safety and efficacy before further studying the combination options. APG990 and APG333 are essential to this combination approach, and this Phase 1 testing is underway. Our lead program, APG777, is being developed as both a monotherapy, initially for atopic dermatitis, and for use in combination treatments. Learn more about our programs below:

Pipeline

Potential best-in-class monotherapy in AD

Higher exposures for better efficacy with less frequent dosing
Program
Program
Preclinical
Phase 1
Phase 2
Phase 3
Next anticipated milestones

APG777

IL-13
Atopic Dermatitis
Atopic Dermatitis
Phase 2
Next anticipated milestones:
Mid-2025: Phase 2 

16-week induction PoC data
1H 2026: Phase 2 
Part A
52-week data
2H 2026: Phase 2 
Part B
16-week data
Asthma
Asthma
Phase 1
Next anticipated milestones:
1H 2025: Phase 1b trial initiation
2H 2025: Phase 2b trial initiation
2026: Phase 1b data
Eosinophilic Esophagitis
Eosinophilic Esophagitis
Phase 1
Next anticipated milestones:
2026: Phase 2 trial initiation

Potential first-or best-in-class combination approaches

Program
Program
Preclinical
Phase 1
Phase 2
Phase 3
Next anticipated milestones

APG777

IL-13

+

APG990

OX40L
Atopic Dermatitis
Atopic Dermatitis
Preclinical
Next anticipated milestones:
2025: Phase 1b PoC trial initiation (vs. DUPIXENT)
2026: Phase 1b PoC data
(vs. DUPIXENT)

APG777

IL-13

+

APG333

TSLP
Asthma
Asthma
Preclinical
2025: additional clinical plan announced
COPD
COPD
Preclinical
2025: additional clinical plan announced

APG808

IL-4Rα

Phase 1b in mild asthma readout expected in 2025

APG990

OX40L

Phase 1 healthy volunteer readout expected in 1H 2025

APG333

TSLP

Phase 1 healthy volunteer readout expected in 2H 2025

Our programs

APG777

APG777 is a novel, subcutaneous half-life extended monoclonal antibody targeting IL-13 for the potential treatment of atopic dermatitis (AD)

In head-to-head preclinical studies, APG777 showed equivalent or better potency to lebrikizumab in the inhibition of IL-13 signaling. AD is a chronic inflammatory skin disorder that affects approximately 40 million adults and 18 million children in the United States, France, Germany, Italy, Japan, Spain and the United Kingdom, 40 percent of which have moderate-to-severe disease.

APG777 is currently in a Phase 2 study for the treatment of moderate-to-severe AD. Based on initial clinical data, the company plans to initiate a Phase 2 trial in asthma and a Phase 1 in eosinophilic esophagitis with plans to further evaluate opportunities to develop APG777 for other I&I indications including chronic rhinosinusitis with nasal polyps, chronic spontaneous urticaria and prurigo nodularis.

APG777

+

APG990

APG777 + APG990 is designed to address multiple immune signaling intervention points through the dual inhibition of IL-13 and OX40L, which we believe could provide potential first-in-class combination treatment for people living with AD and other I&I indications.

Apogee plans to develop APG777 and APG990 together as a potential first-in-class coformulation combining deep and sustained inhibition of Type 2 inflammation via APG777’s inhibition of IL-13 with broader inhibition of Type 1-3 inflammation through APG990’s inhibition of OX40L.

In preclinical studies, the combination of APG777 + APG990 has been shown to drive closer to JAK-like inhibition of Type 1, 2, and 3 signaling compared to approved or in-development biologics, with the potential for best-in-class dosing and better tolerability in AD and a variety of other I&I diseases.

APG777

+

APG333

APG777 + APG333 is designed to address both central and local drivers of obstructive airway disease and potentially break through the efficacy ceiling observed with monotherapies in asthma and COPD.

Apogee plans to evaluate APG777 and APG333 monotherapies in respective Phase 1b trials in patients with asthma in 2025 to support advancement into future combination trials in asthma and COPD.

In preclinical studies, the combination of APG777 + APG333 has been shown to drive broader and deeper inhibition of inflammation centrally with deeper impact on local airway responses compared to approved or in-development biologics, with the potential for a significantly less frequent dosing schedule.